Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 45 Products per page

Entrectinib
Read More
Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
August 30, 2018
Find out more
Ixempra
Read More
Ixempra (ixabepilone; R-Pharm/Otsuka) is a lactam analog of epothilone B that binds to microtubules via tubulin.
February 4, 2016
Find out more
Ebola KOL Interview #1

$599.00

So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.
November 2, 2014
Find out more
Vraylar
Read More
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor.
March 29, 2018
Find out more
Elafibranor
Read More
Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating these receptors increases insulin sensitivity and fatty acid oxidation, which results in a reduction of fat buildup in the liver and leads to a decrease in fibrosis and inflammation.
July 22, 2019
Find out more
Toujeo
Read More
Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot.
November 7, 2017
Find out more
Vosevi
Read More
Vosevi ([sofosbuvir + velpatasvir + voxilaprevir]) is Gilead’s third-generation, pan-genotypic, interferon-free regimen. The fixed-dose combination contains the hepatitis C virus nucleotide NS5B inhibitor sofosbuvir, a second-generation NS5A inhibitor (velpatasvir), and the company’s NS3 protease inhibitor (voxilaprevir).
November 6, 2017
Find out more
Palbociclib for Breast Cancer

$89.00

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
February 1, 2014
Find out more
Disease Analysis: Pulmonary Hypertension
Read More
Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.
May 20, 2022
Find out more
Key Trends in BRICMIST Market Access

$2,995.00

Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey – known collectively as the BRIC/MIST countries – have been a source of welcome growth for a pharmaceutical industry struggling to generate significant gains in its traditional core markets.
October 17, 2016
Find out more
2015 Chronic Lymphocytic Leukemia (CLL) Pulse

$599.00

We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.
January 27, 2015
Find out more
Drug Pricing and Market Access KOL Interview

$599.00

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.
February 1, 2016
Find out more
Dyslipidemia and Diabetes Reimbursement KOL Interview:

$599.00

Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin
August 5, 2015
Find out more
Ovarian Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.
April 2, 2020
Find out more
Remicade
Read More
Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis.
August 2, 2018
Find out more
RSV F Vaccine
Read More
RSV F vaccine is an intramuscular recombinant nanoparticle vaccine comprising a highly purified post-fusion form of the RSV F protein that can be administered with or without an alum adjuvant.
October 5, 2018
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

$599.00

An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.
March 17, 2022
Find out more
France Regulatory Issues

$2,995.00

The much-criticized delay in the removal of marketing authorization for Servier’s Mediator in France has had profound implications for reform of the country’s regulatory system.
November 2, 2016
Find out more
Disease Analysis: NHL: Follicular Lymphoma
Read More
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.
March 10, 2022
Find out more
Opioids and Chronic Neuropathic Pain Management KOL Interview

$599.00

Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.
March 9, 2017
Find out more
Singulair
Read More
Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.
February 16, 2018
Find out more
Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

$599.00

In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.
October 12, 2018
Find out more
Product Launch and Commercialization Strategies

$2,995.00

Recent years have seen changes in the marketplace that have made successful new drug launches difficult to achieve. Many therapy areas are becoming hypercompetitive, with similar treatments jostling for position, and even those products with evidence of superior efficacy or better tolerability still have to overcome reimbursement hurdles.
December 12, 2016
Find out more
Trulicity
Read More
Trulicity (dulaglutide; Eli Lilly) is approved for the treatment of type 2 diabetes. It is a sustained-release formulation glucagon-like peptide-1 (GLP-1) agonist and therefore acts on the incretin system.
November 7, 2017
Find out more
Savaysa
Read More
Savaysa (edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
March 15, 2018
Find out more
Eliquis
Read More
Eliquis (apixaban; Bristol-Myers Squibb/Pfizer) is an orally available factor Xa inhibitor indicated for the prevention of venous thromboembolsim.
March 15, 2018
Find out more
Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

$599.00

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.
March 9, 2017
Find out more
Market Spotlight: Neuropathic Pain

$1,318.00

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
July 28, 2022
Find out more
Extremity Replacement Implants

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for extremities replacement implants. Market forecasts and competitive analyses are provided for the shoulder, elbow, ankle, and small joint arthroplasty devices markets. Geographic segments covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.
December 21, 2020
Find out more
Market Spotlight: Venous Thromboembolism (VTE)

$1,318.00

This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
July 18, 2022
Find out more
Rheumatoid Arthritis Payer Interview – Pennsylvania, US

$599.00

A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.
August 22, 2019
Find out more
Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

$599.00

A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.
February 4, 2019
Find out more
Spain, Neurological Market Opportunities: Disease Incidence and Prevalence, And Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain
December 3, 2012
Find out more
Prostate Cancer KOL Interview – US, Northeast #1

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.
February 9, 2022
Find out more
Bone Grafts and Substitutes

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for bone grafts and substitutes. Product segments covered by this report include allografts and synthetic bone substitutes, growth factors, and cellular bone matrices.
February 15, 2022
Find out more
Feraccru
Read More
Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) is a novel oral ferric iron form with hematinic activity being investigated for the treatment of anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

$1,318.00

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 18, 2022
Find out more
Japan Regulatory Issues

$2,995.00

Historically Japan has been plagued with delays, with new drug approvals sometimes taking three or four years longer than in the US and EU.
November 2, 2016
Find out more
Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

$599.00

An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.
November 19, 2018
Find out more
Drug Delivery: Injection Devices

$4,750.00

Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is commonly regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. In 2021, combined sales of the injection devices covered by this report totaled nearly $5.7bn.
March 15, 2022
Find out more
Zinbryta
Read More
Zinbryta is a humanized monoclonal antibody that selectively binds to the alpha chain (cluster of differentiation [CD]25) of the interleukin-2 receptor on activated T cells to prevent the immunoactivation of MS.
November 24, 2017
Find out more
Mirvetuximab Soravtansine
Read More
Mirvetuximab soravtansine (ImmunoGen) is a folate receptor alpha (FRa)-targeted antibody-drug conjugate (ADC) in development for advanced ovarian cancer patients that overexpress FRa. It is comprised of an FRa-targeted monoclonal antibody linked to the cytotoxic effector compound maytansinoid DM4.
August 17, 2017
Find out more
Oncology Pathways in the US – Friend or Foe for Pharma

$7,500.00

This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways.
July 31, 2015
Find out more
Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

$4,750.00

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft tissue fixation implants for the US, five major EU markets, Japan, and the rest of the world.
April 19, 2019
Find out more
Sorilux
Read More
Following its 2010 launch, Sorilux (calcipotriene; Stiefel/GlaxoSmithKline) has experienced slow

uptake in the psoriasis market, despite having the financial support of GlaxoSmithKline. This comes as

no surprise as the US psoriasis market is saturated with several types of established calcipotriene

formulations, limiting Sorilux’s uptake.
August 26, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *